Zhejiang Hisun Pharmaceutical (600267) Fundamentals 2026 — P/E 20.5x, Revenue Analysis | SniperIQ
Zhejiang Hisun Pharmaceutical (600267) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥14.7B, trading at ¥12.48 on the SHH. This SniperIQ fundamentals page covers Zhejiang Hisun Pharmaceutical's valuation (P/E 20.5x, P/B 1.6x), profitability (net margin 6.8%), revenue (¥10.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhejiang Hisun Pharmaceutical's market cap?
Zhejiang Hisun Pharmaceutical (600267) has a market capitalization of approximately ¥14.7B, trading at ¥12.48 on the SHH. Market cap moves with the live share price.
What is Zhejiang Hisun Pharmaceutical's P/E ratio?
Zhejiang Hisun Pharmaceutical's trailing twelve-month P/E ratio is 20.5x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhejiang Hisun Pharmaceutical?
Zhejiang Hisun Pharmaceutical runs a net profit margin of 6.8%, a gross margin of 46.4%, and an operating margin of 9.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhejiang Hisun Pharmaceutical generate?
Zhejiang Hisun Pharmaceutical reported revenue of ¥10.5B for fiscal year 2025, with net income of ¥541M and earnings per share (EPS) of 0.46. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhejiang Hisun Pharmaceutical pay a dividend?
Zhejiang Hisun Pharmaceutical offers a trailing dividend yield of about 1.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zhejiang Hisun Pharmaceutical financially healthy?
Zhejiang Hisun Pharmaceutical carries a debt-to-equity ratio of 0.16x and a current ratio of 1.00x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhejiang Hisun Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang Hisun Pharmaceutical (600267) the key facts are: market cap ¥14.7B, P/E 20.5x, revenue ¥10.5B, 52-week range 9.35-12.77. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhejiang Hisun Pharmaceutical's full fundamentals live
Get Zhejiang Hisun Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.